We are live on
!
Find out more
First Trust Advisors Portfolio holdings
AUM
$140B
1-Year Est. Return
27.84%
This Fund
S&P 500
This Quarter
Est. Return
+7.26%
1 Year Est. Return
+27.84%
3 Year Est. Return
+78.79%
5 Year Est. Return
+98.89%
10 Year Est. Return
+456.9%
AUM
$29.6B
AUM Growth
+$4.22B
(+17%)
Cap. Flow
+$2.91B
Cap. Flow
% of AUM
9.83%
Top 10 Holdings %
Top 10 Hldgs %
7.91%
Holding
2,390
New
174
Increased
1,221
Reduced
844
Closed
147
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETF
HYLS
|
+$184M |
| 2 |
First Trust NYSE Arca Biotechnology Index Fund
FBT
|
+$158M |
| 3 |
First Trust Health Care AlphaDEX Fund
FXH
|
+$136M |
| 4 |
First Trust Dow Jones Internet Index Fund ETF
FDN
|
+$123M |
| 5 |
First Trust Consumer Staples AlphaDEX Fund
FXG
|
+$123M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$120M |
| 2 |
Conagra Brands
CAG
|
+$72.2M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
+$61.5M |
| 4 |
RAD
Rite Aid Corporation
RAD
|
+$55.9M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$50.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 12.87% |
| 3 | Consumer Discretionary | 10.2% |
| 4 | Consumer Staples | 9.25% |
| 5 | Industrials | 7.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBST
51
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $96.7M | 0.33% |
960,734
+803,110
| +510% | +$62.4M |
|
52
Ionis Pharmaceuticals
IONS
$9.38B
| $96.3M | 0.32% |
+1,559,143
| New | +$76.9M |
|
53
Tyson Foods
TSN
$20B
| $94.6M | 0.32% |
2,358,833
-62,549
| -3% | -$2.54M |
|
54
Akamai
AKAM
$17.1B
| $91.7M | 0.31% |
1,456,374
+72,046
| +5% | +$4.34M |
|
|
GMCR
55
DELISTED
KEURIG GREEN MTN INC
GMCR
| $91.1M | 0.31% |
688,020
+151,140
| +28% | +$21.4M |
|
56
Incyte
INCY
$23.5B
| $90.8M | 0.31% |
1,241,508
-745,018
| -38% | -$48.7M |
|
57
ConocoPhillips
COP
$146B
| $89.5M | 0.3% |
1,296,608
+301,650
| +30% | +$21.1M |
|
58
Philip Morris
PM
$302B
| $89.4M | 0.3% |
1,097,464
+195,627
| +22% | +$16.8M |
|
59
IBM
IBM
$203B
| $87.6M | 0.3% |
571,236
+128,504
| +29% | +$20.4M |
|
60
AbbVie
ABBV
$458B
| $87.6M | 0.3% |
1,338,505
-5,331
| -0.4% | -$336K |
|
61
Ingredion
INGR
$6.34B
| $87.2M | 0.29% |
1,027,850
+274,799
| +36% | +$21.9M |
|
62
Quest Diagnostics
DGX
$25.1B
| $86.1M | 0.29% |
1,284,387
+22,238
| +2% | +$1.4M |
|
63
Cencora
COR
$60.3B
| $85.2M | 0.29% |
944,481
-26,101
| -3% | -$2.24M |
|
|
NPSP
64
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $85M | 0.29% |
+2,375,580
| New | +$70.9M |
|
65
Alkermes
ALKS
$8.87B
| $84.5M | 0.29% |
1,442,735
+627,340
| +77% | +$32M |
|
|
LNKD
66
DELISTED
LinkedIn Corporation
LNKD
| $83.2M | 0.28% |
362,292
+74,563
| +26% | +$16.2M |
|
67
Alnylam Pharmaceuticals
ALNY
$36.4B
| $83.2M | 0.28% |
+857,683
| New | +$79.5M |
|
68
Sysco
SYY
$39.6B
| $83.1M | 0.28% |
2,093,024
+1,229,842
| +142% | +$47.7M |
|
69
Consolidated Edison
ED
$41.6B
| $82.5M | 0.28% |
1,249,939
+403,620
| +48% | +$25.3M |
|
|
JNPR
70
DELISTED
Juniper Networks
JNPR
| $80.8M | 0.27% |
3,618,422
+1,138,246
| +46% | +$24.2M |
|
71
Nektar Therapeutics
NKTR
$2.4B
| $77.7M | 0.26% |
334,248
-74,820
| -18% | -$16M |
|
|
QGENF
72
DELISTED
QIAGEN NV
QGENF
| $77.5M | 0.26% |
3,302,468
+592,764
| +22% | +$13.9M |
|
|
SCG
73
DELISTED
Scana
SCG
| $76.8M | 0.26% |
1,270,918
+556,110
| +78% | +$30.8M |
|
74
Expedia Group
EXPE
$31.7B
| $76.7M | 0.26% |
898,711
+87,160
| +11% | +$7.39M |
|
|
CA
75
DELISTED
CA, Inc.
CA
| $76.1M | 0.26% |
2,497,703
+144,792
| +6% | +$4.23M |
|
Similar funds
DAM
First Trust Advisors's Q4 2014 Portfolio in Review
As of Q4 2014, First Trust Advisors held 2,390 positions worth $29.6B, up 17% from $25.4B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
First Trust Advisors deployed $2.91B of net new capital in Q4 2014, opening 174 new positions and adding to 1,221 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 857,683 shares worth $83.2M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was iShares iBoxx $ High Yield Corporate Bond ETF, an estimated $120M trimmed.
- First Trust Advisors's largest Q4 2014 buy was Alnylam Pharmaceuticals: 857,683 shares worth $83.2M.
- First Trust Advisors added most to First Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETF in Q4 2014, an estimated $184M increase.
- First Trust Advisors's biggest Q4 2014 reduction was iShares iBoxx $ High Yield Corporate Bond ETF, cutting an estimated $120M.
- First Trust Advisors fully exited Immunogen Inc in Q4 2014, selling an estimated $61.5M.
- First Trust Advisors's ten largest holdings make up 7.9% of its $29.6B portfolio in Q4 2014.
- First Trust Advisors opened 174 new positions and closed 147 in Q4 2014.
- First Trust Advisors's portfolio value rose 17% quarter-over-quarter to $29.6B.
Based on First Trust Advisors's 13F filing for Q4 2014, filed 13 Feb 2015.